Evaluation of the Contribution of Transoral Robotic-assisted Surgery Using Da Vinci Xi for Head and Neck Tumors (TORS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Head and Neck cancers are treated either with surgical resection followed by adjuvant radiotherapy, or with organ preservation strategies using definitive radiotherapy with or without concomitant chemotherapy. These treatments have long-time functional side effects and consequences on the quality of life. Transoral robotic surgery has been developing since 2006 by Weinstein and O'Malley in alternative to open surgery, to decrease the morbidity of the large surgical approach. The da Vinci device had the FDA approval and the CE mark in 2009 for transoral surgery of head and neck cancers, using previous generations of da Vinci. The last generation da Vinci Xi has received the FDA approval for laparoscopic surgery in april 2014 and the CE mark in june 2014 but has not been evaluated yet in transoral surgery. The objective of our study is therefore to study the feasibility of this transoral robotic surgery for head and neck cancers, using the da Vinci Xi.
Condition or disease
Head and Neck Cancer
Device: Transoral robotic-assisted surgery with Da Vinci Xi
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient >/= 18
WHO Status 0-2
ENT cancer or solid tumor histologically proven regardless histology
All maps of the head and neck and any stage
surgically resectable according to clinical examination and preoperative investigations, confirmed in multidisciplinary meeting
Or after induction chemotherapy
Or local recurrence regardless of the previous treatment
Or second location in irradiated
Transoral exposition of tumor, assessed preoperatively during endoscopy during the balance of extension of the lesion
The patient must have accepted the possibility of surgical conversion open surgery
The patient must have been clearly informed of the study and have formulated his non-opposition to participate
Metastasis (s) clinical or radiological remote, inaccessible (s) to a local curative treatment
post-treatment tumor progression and / or early recurrence < 3 months
Unresectable tumor by robotic transorally: bone infiltration, deep infiltration of soft tissues, unresectable lymphadenopathy
Contraindications to the suspension for transoral tumor Exposure: Dental fragility against-indication for cervical extension
Pathology against intercurrent-indicating cancer surgery
Inability to submit to medical monitoring study for geographical, social or psychological.